देश: यूनाइटेड किंगडम
भाषा: अंग्रेज़ी
स्रोत: MHRA (Medicines & Healthcare Products Regulatory Agency)
Naproxen
Accord-UK Ltd
M01AE02
Naproxen
250mg
Gastro-resistant tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 10010100; GTIN: 5012617019752
350x210 Leaflet Reel Fed Profile Landscape (BST) Dimensions: Component: Date Sent: Technologist: TECHNICALLY APPROVED Pharmacode: JDE No.: Period Pain Reliever, Gastro- resistant Tablets, 250mg, 9s - UK 350x210 (Reel Fed) 50996221 Leaflet for Blisters 6559 RH 14-12-2020 * Please note that ONLY Artwork Studio is permitted to make changes to the above artwork. No changes are permitted by any 3rd party other than added notes and mark ups for required changes. approved for print/date PROOF ROUND Technical Approval NON PRINTING COLOURS COLOURS DATE SENT: DATE RECEIVED: Item number: ORIGINATOR: ORIGINATION DATE: REVISION DATE: REVISED BY: DIMENSIONS: MIN BODY TEXT SIZE: SUPPLIER: 1. 2. 3. 4. 5. 6. 1. 2. 3. EU-Artwork-Support@accord-healthcare.com NAPROXEN 250MG GASTRO-RESISTANT TABLET PIL - UK Black Profile BBBB0029 NM 15/12/2020 24/02/2021 NM 350x210 (reel fed) 10 pts Accord Barnstaple N/A 06 Version 7 12.02.2020 Cartons and label leaflets only (labels only when specified) page 1 page 4 50996221 BBBB0029 READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. • Keep this leaflet. You may need to read it again. • Ask your pharmacist if you need more information or advice. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. • You must talk to a doctor if you do not feel better or if you feel worse after 3 days. WHAT IS IN THIS LEAFLET 1 WHAT PERIOD PAIN RELIEVER IS AND WHAT IT IS USED FOR 2 WHAT YOU NEED TO KNOW BEFORE YOU TAKE PERIOD PAIN RELIEVER 3 HOW TO TAKE PERIOD PAIN RELIEVER 4 POSSIBLE SIDE EFFECTS 5 HOW TO STORE PERIOD PAIN RELIEVER 6 CONTENTS OF THE PACK AND OTHER INFORMATION 1 WHAT PERIOD PAIN RELIEVER IS AND WHAT IT IS USED FOR Naproxen belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). Period Pa पूरा दस्तावेज़ पढ़ें
OBJECT 1 PERIOD PAIN RELIEVER 250MG GASTRO- RESISTANT TABLETS Summary of Product Characteristics Updated 21-Dec-2022 | Accord-UK Ltd • 1. Name of the medicinal product • 2. Qualitative and quantitative composition • 3. Pharmaceutical form • 4. Clinical particulars • 4.1 Therapeutic indications • 4.2 Posology and method of administration • 4.3 Contraindications • 4.4 Special warnings and precautions for use • 4.5 Interaction with other medicinal products and other forms of interaction • 4.6 Fertility, pregnancy and lactation • 4.7 Effects on ability to drive and use machines • 4.8 Undesirable effects • 4.9 Overdose • 5. Pharmacological properties • 5.1 Pharmacodynamic properties • 5.2 Pharmacokinetic properties • 5.3 Preclinical safety data • 6. Pharmaceutical particulars • 6.1 List of excipients • 6.2 Incompatibilities • 6.3 Shelf life • 6.4 Special precautions for storage • 6.5 Nature and contents of container • 6.6 Special precautions for disposal and other handling • 7. Marketing authorisation holder • 8. Marketing authorisation number(s) • 9. Date of first authorisation/renewal of the authorisation • 10. Date of revision of the text 1. Name of the medicinal product Naproxen 250mg Gastro-resistant Tablets Period Pain Reliever 250mg Gastro-resistant Tablets Boots Period Pain Reliever 250mg Gastro-resistant Tablets Well Pharmaceuticals Period Pain Reliever 250mg Gastro-resistant Tablets 2. Qualitative and quantitative composition Each tablet contains: 250mg Naproxen Excipient(s) with known effect Each gastro-resistant tablet contains 74.00mg of lactose. For a full list of excipients, see section 6.1 3. Pharmaceutical form Gastro-resistant tablets. White, round, biconvex enteric-coated tablets. 4. Clinical particulars 4.1 Therapeutic indications Indicated for the treatment of primary dysmenorrhoea in women aged 15 to 50 years. 4.2 Posology and method of administration Posology Adolescents (post puberty) and adult females between the ages of 15 and 50: On the पूरा दस्तावेज़ पढ़ें